3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Psoriasis
1
Periodic Fevers Syndrome
1
Motor Activity
1
Lymphoma, Follicular
1
Crohn Disease
1
Arthritis, Rheumatoid
1
Interventions
tofacitinib
7
Etanercept
4
Methotrexate
2
Adalimumab
2
sodium luminolate
1
secukinumab
1
ixekizumab
1
baricitinib
1
apremilast
1
abrocitinib
1
Vitamin D
1
Vaccines
1
Saline Solution
1
Herpes Zoster Vaccine
1
Folic Acid
1
Fish Oils
1
Fatty Acids, Omega-3
1
Eicosapentaenoic Acid
1
Docosahexaenoic Acids
1
Cholecalciferol
1
Anti-Infective Agents, Local
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Psoriasis
×
secukinumab
×
Clear all
NCT01961609
2019-03-18
SIGNATURE
Novartis
Phase 3
Completed
235 enrolled
23 charts